Ouvrir le menu
Publier un document
Alternate Text
clear
fr
Ouvrir le menu
bristol-myers-squibb
audio

Editeur

bristol-myers-squibb

Publications

Derniers ajouts
chevron
European Researchers Invited to Submit Study Proposals for Bristol-Myers Squibb s Partnering for Cure™ Virology Research Programme
Category

Documents

European Researchers Invited to Submit Study Proposals for Bristol-Myers Squibb's Partnering for Cure™ Virology Research Programme

European Researchers Invited to Submit Study Proposals for Bristol-Myers Squibb s Partnering for Cure™ Virology Research Programme Alternate Text
Category

Documents

Médias

European Researchers Invited to Submit Study Proposals for Bristol-Myers Squibb's Partnering for Cure™ Virology Research Programme

Book

7 pages

Flag

English

icon play Lire
icon play Infos
YERVOY®(ipilimumab) Receives Marketing Authorisation for First-Line Treatment of Adult Patients with Advanced Melanoma in Europe
Category

Documents

YERVOY®(ipilimumab) Receives Marketing Authorisation for First-Line Treatment of Adult Patients with Advanced Melanoma in Europe

YERVOY®(ipilimumab) Receives Marketing Authorisation for First-Line Treatment of Adult Patients with Advanced Melanoma in Europe Alternate Text
Category

Documents

Médias

YERVOY®(ipilimumab) Receives Marketing Authorisation for First-Line Treatment of Adult Patients with Advanced Melanoma in Europe

Book

11 pages

Flag

English

icon play Lire
icon play Infos
Subcutaneous Formulation of ORENCIA® (abatacept) Approved by European Commission
Category

Documents

Subcutaneous Formulation of ORENCIA® (abatacept) Approved by European Commission

Subcutaneous Formulation of ORENCIA® (abatacept) Approved by European Commission Alternate Text
Category

Documents

Médias

Subcutaneous Formulation of ORENCIA® (abatacept) Approved by European Commission

Book

3 pages

Flag

English

icon play Lire
icon play Infos
New Four- and Five-Year Survival Data for YERVOY® (ipilimumab) in Treatment-Naïve and Previously-Treated Metastatic Melanoma Presented at the ESMO 2012 Congress (European Society for Medical Oncology)
Category

Documents

New Four- and Five-Year Survival Data for YERVOY® (ipilimumab) in Treatment-Naïve and Previously-Treated Metastatic Melanoma Presented at the ESMO 2012 Congress (European Society for Medical Oncology)

New Four- and Five-Year Survival Data for YERVOY® (ipilimumab) in Treatment-Naïve and Previously-Treated Metastatic Melanoma Presented at the ESMO 2012 Congress (European Society for Medical Oncology) Alternate Text
Category

Documents

Médias

New Four- and Five-Year Survival Data for YERVOY® (ipilimumab) in Treatment-Naïve and Previously-Treated Metastatic Melanoma Presented at the ESMO 2012 Congress (European Society for Medical Oncology)

Book

4 pages

Flag

English

icon play Lire
icon play Infos
World Hepatitis Alliance (the Alliance), European Liver Patient Association (ELPA) and Bristol-Myers Squibb Announce Global Expansion of PATH B Programme on World Hepatitis Day to Address the Unmet Need in Resources for People Living with Chronic Hepatitis B
Category

Documents

World Hepatitis Alliance (the Alliance), European Liver Patient Association (ELPA) and Bristol-Myers Squibb Announce Global Expansion of PATH B Programme on World Hepatitis Day to Address the Unmet Need in Resources for People Living with Chronic Hepatitis B

World Hepatitis Alliance (the Alliance), European Liver Patient Association (ELPA) and Bristol-Myers Squibb Announce Global Expansion of PATH B Programme on World Hepatitis Day to Address the Unmet Need in Resources for People Living with Chronic Hepatitis B Alternate Text
Category

Documents

Médias

World Hepatitis Alliance (the Alliance), European Liver Patient Association (ELPA) and Bristol-Myers Squibb Announce Global Expansion of PATH B Programme on World Hepatitis Day to Address the Unmet Need in Resources for People Living with Chronic Hepatitis B

Book

3 pages

Flag

English

icon play Lire
icon play Infos
ORENCIA® ▼ (abatacept) Demonstrates Comparable Efficacy to Humira® (adalimumab) in Patients with Moderate to Severe Rheumatoid Arthritis in First Head-to-Head Study of These Agents
Category

Documents

ORENCIA® ▼ (abatacept) Demonstrates Comparable Efficacy to Humira® (adalimumab) in Patients with Moderate to Severe Rheumatoid Arthritis in First Head-to-Head Study of These Agents

ORENCIA® ▼ (abatacept) Demonstrates Comparable Efficacy to Humira® (adalimumab) in Patients with Moderate to Severe Rheumatoid Arthritis in First Head-to-Head Study of These Agents Alternate Text
Category

Documents

Médias

ORENCIA® ▼ (abatacept) Demonstrates Comparable Efficacy to Humira® (adalimumab) in Patients with Moderate to Severe Rheumatoid Arthritis in First Head-to-Head Study of These Agents

Book

2 pages

Flag

English

icon play Lire
icon play Infos
  • Univers Univers
  • Ebooks Ebooks
  • Livres audio Livres audio
  • Presse Presse
  • Podcasts Podcasts
  • BD BD
  • Documents Documents
expand_more
Vote une nouvelle fonctionnalité

Vote pour une nouvelle fonctionnalité YouScribe !
playstore
appstore
facebook twitter instagram youtube

YouScribe

Le catalogue

Le service

Les conditions

© 2010-2024 YouScribe
Livre audio en ligne - Développement personnel Livre en ligne Tout le catalogue Tous les Intérêts
Alternate Text
Category

Book

Book

icon play
icon play Infos